This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Motus GI Holdings Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Motus GI Holdings de 19.3% y 142.2% respectivamente, mientras que el BPA crecerá en un 65.9% al año.

Información clave

19.3%

Tasa de crecimiento de los beneficios

65.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	15.9%
Tasa de crecimiento de los ingresos	142.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	22 Nov 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:7M4 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2024	2	-11	N/A	N/A	2
12/31/2023	0	-13	N/A	N/A	2
9/30/2023	0	-14	-13	-13	N/A
6/30/2023	1	-16	-15	-15	N/A
3/31/2023	1	-18	-17	-17	N/A
12/31/2022	1	-19	-18	-17	N/A
9/30/2022	1	-20	-18	-17	N/A
6/30/2022	0	-20	-17	-17	N/A
3/31/2022	0	-19	-15	-15	N/A
12/31/2021	0	-25	-15	-14	N/A
9/30/2021	0	-25	-14	-13	N/A
6/30/2021	0	-24	-13	-13	N/A
3/31/2021	0	-24	-15	-14	N/A
12/31/2020	0	-19	-17	-17	N/A
9/30/2020	0	-21	-20	-20	N/A
6/30/2020	0	-22	-22	-21	N/A
3/31/2020	0	-23	-22	-22	N/A
12/31/2019	0	-23	-20	-20	N/A
9/30/2019	0	-23	-20	-19	N/A
6/30/2019	0	-23	-18	-17	N/A
3/31/2019	0	-21	-18	-17	N/A
12/31/2018	0	-22	-15	-15	N/A
9/30/2018	0	-20	-14	-13	N/A
6/30/2018	0	-18	-13	-13	N/A
3/31/2018	0	-18	-12	-12	N/A
12/31/2017	N/A	-13	-11	-10	N/A
9/30/2017	N/A	-12	-10	-10	N/A
6/30/2017	N/A	-11	N/A	-8	N/A
3/31/2017	N/A	-9	N/A	-7	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 7M4 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 7M4 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 7M4 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (142.2% al año) de 7M4 crezcan más rápidamente que los del mercado German (5.2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (142.2% al año) de 7M4 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 7M4 se prevé que sea elevada dentro de 3 años.

This company listing is no longer active

Motus GI Holdings Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2025

Recent updates

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

Motus GI Holdings Announces Update on Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Motus GI Holdings, Inc. Announces Executive Changes

New major risk - Financial position

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$1.86 loss in 2Q 2022)

Motus GI Holdings, Inc. Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of Its Pure-Vu® EVS System

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings Provides Shareholder's Equity Compliance Update

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 At the Pentax Learning Center

Motus GI Holdings, Inc. Announces Executive Changes

Motus GI Holdings, Inc. announced that it expects to receive $3.5 million in funding

Motus GI Holdings, Inc. Completes First Clinical Evaluation of New Pure-Vu(R) Gastro in Upper Gastrointestinal Procedures to Support Fda Submission

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.86 loss in 1Q 2022)

Motus GI Holdings Receives Non-Compliance Notice From Nasdaq

Motus GI Holdings, Inc. Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Insufficient new directors

Motus GI Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$1.86 loss per share (vs US$1.99 loss in 2Q 2021)

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

Motus GI Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: US$0.093 loss per share (vs US$0.26 loss in 1Q 2021)

Insufficient new directors

Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.60 loss in FY 2020)

Motus GI Grants 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

Motus GI Holdings, Inc. Receives FDA Clearance to Market the Pure-Vu® EVS System

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2020)

Insufficient new directors

Independent Director Samuel Nussbaum has left the company

Second quarter 2021 earnings released: US$0.099 loss per share (vs US$0.15 loss in 2Q 2020)

Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.23 loss in 1Q 2020)

Forecast to breakeven in 2025

Motus Gi Holdings, Inc. Announces Publication of A Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource

Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento